LAUSR

Vaccines are indeed a boon for tackling the present COVID-19 pandemic. In India, ChAdOx1 nCoV-19 (Covishield) is the most commonly used vaccine in the government vaccination programme for adults more than 18 years of age. It is a recombinant vaccine developed by Oxford-Astra Zeneca and manufactured in India by Serum Institute of India (SSI). Here, we report a case of severe pemphigus vulgaris following the second dose of Covishield vaccination in an adult male. The patient developed septicemia during the course of hospital stay and he was managed with systemic steroids, parenteral antibiotics and intravenous immunoglobulins (IVIg) along with proper wound care. Patient started improving within one month of therapy. This case is being reported in view of the rarity of pemphigus vulgaris following Covishield vaccine.